Download presentation
Presentation is loading. Please wait.
Published byÁgnes Varga Modified over 6 years ago
1
Mometasone furoate nasal spray reduces the ocular symptoms of seasonal allergic rhinitis
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I. Bernstein, MD, Tulin Shekar, MS, Ariel Teper, MD Journal of Allergy and Clinical Immunology Volume 125, Issue 6, Pages e5 (June 2010) DOI: /j.jaci Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Fig 1 Mean change from baseline averaged over days 2 to 15 in total and individual instantaneous (A) and reflective (B) ocular symptoms (all randomized subjects). Brackets represent SEMs. ∗P < .05 versus placebo. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Study design. ∗Screening period of at least 3 days. †Randomization
Study design. ∗Screening period of at least 3 days. †Randomization. MFNS, Mometasone furoate nasal spray; QD, once daily. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
4
Mean change from baseline averaged over days 2 to 15 in total and individual instantaneous (A) and reflective (B) nasal symptoms (all randomized subjects). Brackets represent SEMs. ∗P < .001 versus placebo. MFNS, Mometasone furoate nasal spray; QD, once daily. Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
5
Mean pollen count averaged over 25 sites during the study period.
Journal of Allergy and Clinical Immunology , e5DOI: ( /j.jaci ) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.